Physician
Galion Community Hospital
Galion Community Hospital was paid $25.15M by Medicaid between Jan 2018 and Dec 2024, across 301 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 37% of everything it billed.
33Billing provider infoGALION COMMUNITY HOSPITAL
GALION, OH 44833
GALION, OH 44833
33aNPI1215907522assigned 01/26/2006
33bProvider typeFamily Medicine Physician
28Total paid$25.15M
24GClaims521,232
24DCodes billed301
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#4 of 739
Median peer was paid$30K
This provider vs. median848×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,419 | $1.57M | |
| 2019 | 44,218 | $2.06M | |
| 2020 | 41,260 | $2.41M | |
| 2021 | 47,543 | $2.88M | |
| 2022 | 53,492 | $3.42M | |
| 2023 | 167,819 | $6.31M | |
| 2024incomplete | 129,481 | $6.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 37% | 114,637 | 97,605 | $9.38M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.8% | 21,935 | 20,171 | $2.46M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.5% | 11,494 | 10,178 | $1.37M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.7% | 15,540 | 13,686 | $1.18M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.6% | 10,739 | 9,803 | $912K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 3.6% | 1,457 | 1,388 | $911K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 6,729 | 5,852 | $804K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 8,964 | 2,308 | $654K |
| 80305 | 2.0% | 13,035 | 9,993 | $501K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 5,993 | 5,538 | $467K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,193 | 1,016 | $441K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.6% | 5,094 | 1,809 | $408K |
289 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 4,197 | $376K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 1,116 | $362K |
| 95811 | 1.4% | 654 | $358K | |
| 95886 | 1.4% | 1,610 | $350K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 969 | $252K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 870 | $241K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 712 | $198K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,691 | $192K |
| 64493 | <1% | 305 | $180K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,431 | $140K |
| 59025 | Fetal non-stress test | <1% | 1,019 | $139K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 605 | $130K |
| 20610 | <1% | 1,074 | $119K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,040 | $105K |
| G0378 | Hospital observation service, per hour | <1% | 1,970 | $99K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,420 | $93K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,590 | $90K |
| 97803 | <1% | 891 | $78K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,531 | $68K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,442 | $61K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,134 | $54K |
| 62323 | <1% | 101 | $53K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,770 | $51K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,217 | $50K |
| 92526 | <1% | 732 | $47K | |
| 86850 | <1% | 1,618 | $45K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 192 | $45K |
| 97162 | <1% | 751 | $44K | |
| 87070 | <1% | 3,942 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,492 | $43K |
| 80061 | Lipid panel | <1% | 3,999 | $40K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 970 | $39K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 96 | $39K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 441 | $39K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,177 | $38K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 427 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 200 | $36K |
| 64635 | <1% | 65 | $36K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,794 | $35K |
| 27096 | <1% | 124 | $34K | |
| 71250 | <1% | 426 | $32K | |
| 97016 | <1% | 835 | $31K | |
| 97760 | <1% | 334 | $31K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,203 | $30K |
| 73630 | <1% | 1,847 | $30K | |
| 97014 | <1% | 1,045 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,466 | $28K |
| 97161 | <1% | 443 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,666 | $28K |
| 76830 | Ultrasound, transvaginal | <1% | 333 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,569 | $27K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,306 | $25K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,758 | $25K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 263 | $24K |
| 90686 | <1% | 1,539 | $23K | |
| 86900 | <1% | 1,568 | $23K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,606 | $22K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,216 | $21K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,059 | $21K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 213 | $19K |
| 86140 | <1% | 1,931 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 343 | $19K |
| 82607 | <1% | 1,119 | $18K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 101 | $16K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 802 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,019 | $16K |
| 84439 | <1% | 933 | $15K | |
| 86901 | <1% | 1,568 | $14K | |
| 87081 | <1% | 625 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,374 | $13K |
| 64721 | <1% | 15 | $12K | |
| J3490 | Unclassified drugs | <1% | 1,405 | $12K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 99 | $12K |
| 80069 | <1% | 1,342 | $11K | |
| 97166 | <1% | 109 | $11K | |
| 20611 | <1% | 38 | $11K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 430 | $10K |
| 81002 | <1% | 525 | $9K | |
| 82728 | <1% | 564 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 163 | $9K |
| 94664 | <1% | 525 | $8K | |
| 73610 | <1% | 624 | $8K | |
| 94060 | <1% | 99 | $8K | |
| 83735 | <1% | 3,552 | $8K | |
| 83540 | <1% | 1,066 | $8K | |
| 72110 | <1% | 468 | $8K | |
| 81025 | <1% | 2,272 | $8K | |
| 81003 | <1% | 1,552 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 592 | $7K |
| 80076 | <1% | 1,331 | $7K | |
| 90715 | <1% | 489 | $7K | |
| 82570 | <1% | 895 | $7K | |
| 85027 | <1% | 980 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,599 | $6K |
| 73110 | <1% | 539 | $6K | |
| 86592 | <1% | 916 | $6K | |
| 90670 | <1% | 455 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 341 | $6K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 567 | $6K |
| 87186 | <1% | 1,667 | $6K | |
| 84484 | <1% | 3,504 | $6K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 150 | $6K |
| 76536 | <1% | 51 | $6K | |
| 81001 | <1% | 6,175 | $5K | |
| 86803 | <1% | 648 | $5K | |
| 87077 | <1% | 778 | $5K | |
| 82565 | <1% | 3,800 | $5K | |
| 87088 | <1% | 1,228 | $5K | |
| 87340 | <1% | 550 | $5K | |
| 73030 | <1% | 455 | $5K | |
| 84153 | <1% | 400 | $5K | |
| 85610 | <1% | 1,738 | $5K | |
| 94762 | <1% | 71 | $5K | |
| 84702 | <1% | 429 | $5K | |
| 76770 | <1% | 29 | $4K | |
| 90633 | <1% | 242 | $4K | |
| 73130 | <1% | 457 | $4K | |
| 97802 | <1% | 49 | $4K | |
| 87150 | <1% | 672 | $4K | |
| 82043 | <1% | 621 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 44 | $4K |
| 82746 | <1% | 689 | $4K | |
| 73564 | <1% | 442 | $4K | |
| 64636 | <1% | 65 | $4K | |
| 92250 | <1% | 78 | $3K | |
| 93971 | <1% | 46 | $3K | |
| 83550 | <1% | 607 | $3K | |
| 86701 | <1% | 304 | $3K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 973 | $3K |
| 74018 | <1% | 201 | $3K | |
| 80051 | <1% | 3,551 | $3K | |
| 86038 | <1% | 162 | $3K | |
| 97750 | <1% | 48 | $3K | |
| 86704 | <1% | 210 | $3K | |
| 86706 | <1% | 265 | $3K | |
| 97116 | <1% | 97 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,945 | $3K |
| 83970 | <1% | 87 | $3K | |
| 96376 | <1% | 1,052 | $3K | |
| 95911 | <1% | 13 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,535 | $3K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 104 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,126 | $2K |
| 85652 | <1% | 1,161 | $2K | |
| 73502 | <1% | 184 | $2K | |
| 95885 | <1% | 12 | $2K | |
| 92567 | <1% | 74 | $2K | |
| 84550 | <1% | 430 | $2K | |
| 94727 | <1% | 57 | $2K | |
| 96367 | <1% | 53 | $2K | |
| 84450 | <1% | 408 | $2K | |
| 86708 | <1% | 179 | $2K | |
| 87205 | <1% | 693 | $2K | |
| 73140 | <1% | 189 | $2K | |
| 84156 | <1% | 523 | $2K | |
| 84460 | <1% | 434 | $2K | |
| 20550 | <1% | 21 | $2K | |
| 84703 | <1% | 290 | $2K | |
| 85730 | <1% | 888 | $2K | |
| 97163 | <1% | 12 | $2K | |
| 76801 | <1% | 29 | $2K | |
| 82550 | <1% | 408 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 176 | $2K |
| 84300 | <1% | 436 | $2K | |
| 94729 | <1% | 41 | $2K | |
| 84403 | <1% | 100 | $2K | |
| 85018 | <1% | 89 | $2K | |
| 95910 | <1% | 37 | $1K | |
| 82784 | <1% | 125 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 753 | $1K |
| 83880 | <1% | 625 | $1K | |
| 82948 | <1% | 1,855 | $1K | |
| 84520 | <1% | 3,577 | $1K | |
| 94618 | <1% | 26 | $1K | |
| 82947 | <1% | 3,545 | $1K | |
| 73080 | <1% | 101 | $1K | |
| 83690 | <1% | 2,654 | $1K | |
| 72050 | <1% | 59 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,220 | $1K |
| 95251 | <1% | 1,010 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 106 | $1K |
| 86787 | <1% | 220 | $1K | |
| 93017 | <1% | 12 | $943.38 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 105 | $932.78 |
| 83605 | <1% | 1,229 | $927.37 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $897.62 |
| 80344 | <1% | 170 | $877.37 | |
| 90656 | <1% | 74 | $844.86 | |
| 85045 | <1% | 252 | $827.81 | |
| 84425 | <1% | 97 | $804.02 | |
| 64494 | <1% | 268 | $781.59 | |
| 73562 | <1% | 61 | $761.82 | |
| 84145 | <1% | 194 | $738.91 | |
| 90674 | <1% | 36 | $737.23 | |
| 82950 | <1% | 189 | $709.07 | |
| 86431 | <1% | 30 | $690.86 | |
| 82803 | <1% | 421 | $657.23 | |
| 87449 | <1% | 170 | $639.05 | |
| 90681 | <1% | 132 | $570.10 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,248 | $567.99 |
| 86430 | <1% | 34 | $553.80 | |
| 90698 | <1% | 41 | $511.05 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $507.06 |
| 92551 | <1% | 13 | $464.90 | |
| 92557 | <1% | 14 | $454.18 | |
| 86762 | <1% | 176 | $402.85 | |
| 90734 | <1% | 63 | $401.98 | |
| 86160 | <1% | 26 | $391.54 | |
| 85378 | <1% | 699 | $383.22 | |
| 82270 | <1% | 34 | $371.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,260 | $365.55 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 150 | $351.52 |
| 90710 | <1% | 100 | $330.02 | |
| 80349 | <1% | 75 | $309.06 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 165 | $298.22 |
| 84100 | <1% | 107 | $277.94 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,255 | $270.67 |
| 83516 | <1% | 21 | $234.29 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 985 | $232.99 |
| 82310 | <1% | 61 | $206.07 | |
| 74022 | <1% | 42 | $198.97 | |
| 87040 | <1% | 483 | $194.89 | |
| 72070 | <1% | 18 | $192.24 | |
| 82105 | <1% | 16 | $190.22 | |
| 84590 | <1% | 44 | $186.03 | |
| 90648 | <1% | 48 | $177.46 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 25 | $176.56 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,018 | $168.93 |
| 83655 | <1% | 12 | $164.57 | |
| 90677 | <1% | 12 | $153.27 | |
| 84436 | <1% | 13 | $135.35 | |
| 82150 | <1% | 182 | $109.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 603 | $106.97 |
| 84481 | <1% | 12 | $103.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,656 | $97.48 |
| 90700 | <1% | 13 | $91.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 312 | $88.73 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 178 | $87.07 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 952 | $84.10 |
| 90685 | <1% | 15 | $79.08 | |
| 84238 | <1% | 13 | $77.16 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,011 | $76.20 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,136 | $57.81 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 285 | $52.65 |
| 90697 | <1% | 16 | $50.75 | |
| 85651 | <1% | 26 | $50.57 | |
| 84446 | <1% | 14 | $46.24 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,667 | $41.99 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,509 | $40.40 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 155 | $29.26 |
| 80081 | <1% | 13 | $29.16 | |
| 90474 | <1% | 125 | $27.60 | |
| 82010 | <1% | 19 | $27.02 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 508 | $23.61 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 154 | $22.01 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 28 | $21.01 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 38 | $16.60 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 196 | $15.81 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 367 | $10.75 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 208 | $10.38 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 47 | $8.73 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 439 | $7.63 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 192 | $7.25 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 17 | $7.10 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 88 | $6.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,175 | $6.32 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 777 | $5.80 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 465 | $4.84 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 57 | $4.84 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 181 | $4.59 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 117 | $3.91 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 240 | $2.02 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 19 | $1.47 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 198 | $1.29 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $0.87 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 22 | $0.00 |
| 94761 | 0% | 98 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 20 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 93 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 124 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 34 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 72 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 20 | $0.00 |
| 92015 | Determination of refractive state | 0% | 18 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 21 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 38 | $0.00 |
| 87210 | 0% | 12 | $0.00 | |
| 90461 | 0% | 15 | $0.00 | |
| 01810 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDRAIME, DONALD (CFO)
Parent organizationGALION COMMUNITY HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Avita Ontario Hospital | Ontario, OH | $19.73M |
| Galion Community Hospital | Galion, OH | $80K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.